CytomX Therapeutics announced a significant layoff of 40% of its staff, primarily targeting general and administrative functions, to focus on clinical programs and improve cost flexibility.
The company has no drugs currently on the market and has faced persistent challenges, lacking a successful late-stage trial amidst reliance on revenue from partnerships with larger biotech firms.
Collection
[
|
...
]